Blog Posts

06 Feb 2017
img

Today, Prescription Justice issued a press release announcing new data showing that 45 million Americans did not fill a prescription in 2016 because of drug costs and the publication of its policy report recommending that President Donald Trump take executive actions to help consumers more easily import lower cost medications for personal use. Previously, Prescription Justice reported that 35 million American adults did not fill a prescription because of cost. The new data, extracted from the Commonwealth Fund’s 2016 International Health Policy Survey of Adults, shows the crisis of high drug prices to be worse than is widely reported. (more…)

30 Jan 2017
img

We are proud to announce that we have changed our organization's (DBA) name from Prescription Justice Action Group to Prescription Justice, which is a simpler expression of our core position: making prescription drugs affordable is an issue of justice for Americans and we will help them obtain it.

In addition to our website and logo redesign, we have also added a weekly media update that features top news and journal articles focused on our policy priorities - personal drug importation, Medicare Drug Price Negotiations, and ending "Pay for Delay", - as well as other advocacy efforts about tackling the prescription drug price crisis in America and globally.

Let's all work together to bring about prescription justice!

21 Jan 2017
img

Last week, Senators Bernie Sanders (I-VT) and Amy Klobuchar (D-MN) proposed an amendment (S.A. 178) to the Senate Budget Reconciliation bill that would allow individuals, pharmacies and wholesalers to import prescription medications from Canada and other countries with a valid prescription from a U.S. provider.

The amendment took place during a 7-hour vote-a-rama in which more than 150 amendments were considered and voted on for a brief ten minutes.  The amendment failed 52-46, with 13 Democrats voting against it. While the measure failed to pass, it surprisingly garnered support from 12 Republicans including Senators Ted Cruz and Rand Paul. It’s worth noting that Senators Chuck Schumer (D-NY) and Kristen Gillibrand (D-NY) voted against the Dorgan-Snowe importation amendment in 2009, voted yes this time around. (more…)

06 Jan 2017
img

Value-based pharmaceutical pricing, aimed at achieving better value for pharmaceutical spending and lowering drug prices, while maintaining innovation, is a concept that is gaining traction.  In the U.S., prescription drug prices are set by pharmaceutical companies to maximize profits, not based on how well a drug works. In contrast, according to its proponents, value-based drug pricing would mean real health outcomes (not just profits) determine the cost of a drug.  

President-Elect Trump’s push for healthcare reform that focuses on free market, consumer-driven initiatives will enhance the political viability of value-based drug pricing. It has more support by the pharmaceutical industry than other popular policies to bring down drug prices, as it’s viewed as more in line with free market principles than other policy proposals, such as allowing Medicare to negotiate drug prices. 

(more…)

12 Dec 2016
img

The pharmaceutical industry often defends shameful price gouging of consumers by arguing that their high profits fund the research and development of tomorrow’s new miracle cures. There is robust debate about the degree to which lowering drug prices would hurt pharmaceutical innovation. The current system holds consumers and governments hostage to pharmaceutical company business models in a manner that is inherently unethical. Think of the cancer patient who has to shell out $30,000 in co-insurance to live, and if not, then die.

The concept and practice of “delinkage,” in which the invention of new medicines is delinked from high drug prices transcends this old debate and envisions a brighter more humane future…one with robust pharmaceutical innovation.

(more…)